Skip to main content

Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel

Tumor Biology volume 37, pages 10539–10544 (2016)Cite this article

Abstract

Paclitaxel is a chemotherapeutic drug that is effective for treating non-small cell lung cancer (NSCLC). However, some NSCLCs are not sensitive to paclitaxel treatment with undetermined underlying molecular mechanisms. In this study, we found that paclitaxel dose-dependently activated Beclin-1 in 2 NSCLC cell lines, A549 and Calu-3. Inhibition of autophagy significantly increased the paclitaxel-induced NSCLC cell death in a cell counting kit-8 (CCK-8) assay. Moreover, microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells. Bioinformatics study showed that miR-216b targeted the 3′-UTR of Beclin-1 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay. Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death. Strategies that increase miR-216b levels or inhibit cell autophagy may improve the outcome of paclitaxel treatment in NSCLC therapy.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Caramori G, Casolari P, Cavallesco GN, Giuffre S, Adcock I, Papi A. Mechanisms involved in lung cancer development in COPD. Int J Biochem Cell Biol. 2011;43:1030–44.

    CAS  Article  PubMed  Google Scholar 

  2. Buttery RC, Rintoul RC, Sethi T. Small cell lung cancer: the importance of the extracellular matrix. Int J Biochem Cell Biol. 2004;36:1154–60.

    CAS  Article  PubMed  Google Scholar 

  3. Pei J, Lou Y, Zhong R, Han B. MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.

    CAS  Article  PubMed  Google Scholar 

  4. Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–81.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang CM. Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in taxol((r))-resistant ovarian cancer. Am J Transl Res. 2015;7:841–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. D'Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, et al. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cell Physiol Biochem. 2015;35:2006–18.

    Article  PubMed  Google Scholar 

  7. Yun M, Lee D, Park MN, Kim EO, Sohn EJ, Kwon BM, et al. Cinnamaldehyde derivative (CB-PIC) sensitizes chemo-resistant cancer cells to drug-induced apoptosis via suppression of MDR1 and its upstream STAT3 and AKT signalling. Cell Physiol Biochem. 2015;35:1821–30.

    CAS  Article  PubMed  Google Scholar 

  8. He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem. 2014;33:173–84.

    CAS  Article  PubMed  Google Scholar 

  9. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157:65–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Chen Y, Liu H, Guan Y, Wang Q, Zhou F, Jie L, et al. The altered autophagy mediated by TFEB in animal and cell models of amyotrophic lateral sclerosis. Am J Transl Res. 2015;7:1574–87.

    PubMed  PubMed Central  Google Scholar 

  11. Chen J, Wang Q, Yin FQ, Zhang W, Yan LH, Li L. MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy. Am J Transl Res. 2015;7:1510–27.

    PubMed  PubMed Central  Google Scholar 

  12. Nandi SS, Duryee MJ, Shahshahan HR, Thiele GM, Anderson DR, Mishra PK. Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading. Am J Transl Res. 2015;7:683–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155:1216–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401–10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, et al. Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer. Sci Rep. 2015;5:14045.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014;11:508–16.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, et al. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol. 2013;27:280–95.

    CAS  Article  PubMed  Google Scholar 

  19. Zhu Y, He W, Gao X, Li B, Mei C, Xu R, et al. Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Sci Rep. 2015;5:17730.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Zhu X, Ruan Z, Yang X, Chu K, Wu H, Li Y, et al. Connexin 31.1 degradation requires the clathrin-mediated autophagy in NSCLC cell H1299. J Cell Mol Med. 2015;19:257–64.

    CAS  Article  PubMed  Google Scholar 

  21. Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. Oncotarget. 2014;5:4765–78.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ali AB, Nin DS, Tam J, Khan M. Role of chaperone mediated autophagy (CMA) in the degradation of misfolded N-CoR protein in non-small cell lung cancer (NSCLC) cells. PLoS One. 2011;6:e25268.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Di Leva G, Croce CM. MiRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.

    CAS  Article  PubMed  Google Scholar 

  25. Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.

    CAS  Article  PubMed  Google Scholar 

  27. Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.

    CAS  Article  PubMed  Google Scholar 

  28. Kim SY, Lee YH, Bae YS. Mir-186, mir-216b, mir-337-3p, and mir-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells. Biochem Biophys Res Commun. 2012;429:173–9.

    CAS  Article  PubMed  Google Scholar 

  29. Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang EL, Wu ZB, et al. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis. 2015;6:e1670.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, et al. MiR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci. 2011;124:2997–3005.

    CAS  Article  PubMed  Google Scholar 

  31. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015;6:7899–917.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.

    CAS  Article  PubMed  Google Scholar 

  33. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;59:221–6.

    CAS  Article  PubMed  Google Scholar 

  34. Coronnello C, Benos PV. ComiR: combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013;41:W159–64.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–20.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12:514–27.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007;11:498–512.

    CAS  Article  PubMed  Google Scholar 

  38. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446:815–9.

    CAS  Article  PubMed  Google Scholar 

  39. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol. 2007;18 Suppl 12:xii15–20.

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Thoracic Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, 110000, China

    Kan Chen & Wenjun Shi

Authors
  1. Kan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenjun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenjun Shi.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, K., Shi, W. Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel. Tumor Biol. 37, 10539–10544 (2016). https://doi.org/10.1007/s13277-016-4929-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4929-x

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Paclitaxel
  • Autophagy
  • Beclin-1
  • miR-216b